171.30Open171.30Pre Close0 Volume1 Open Interest80.00Strike Price0.00Turnover390.58%IV3.73%PremiumJan 17, 2025Expiry Date162.26Intrinsic Value100Multiplier24DDays to Expiry9.04Extrinsic Value100Contract SizeAmericanOptions Type0.9459Delta0.0004Gamma1.41Leverage Ratio-0.5588Theta0.0385Rho1.34Eff Leverage0.0686Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet